[1] Baveno Ⅷ Faculty. Baveno Ⅷ-Advancing consensus in portal hypertension[J/OL]. J Hepatol,2026.https://pubmed.ncbi.nlm.nih.gov/42624290/ [2] de Franchis R,Pascal JP,Ancona E,et al. Definitions, methodology and therapeutic strategies in portal hypertension. A consensus development workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990[J]. J Hepatol,1992,15(1/2):256-261. [3] de Franchis R. Developing consensus in portal hypertension[J]. J Hepatol,1996,25(3):390-394. [4] de Franchis R. Updating consensus in portal hypertension: report of the Baveno Ⅲ Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension[J]. J Hepatol,2000,33(5):846-852. [5] de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno Ⅳ consensus workshop on methodology of diagnosis and therapy in portal hypertension[J]. J Hepatol,2005,43(1):167-176. [6] de Franchis R. Revising consensus in portal hypertension: report of the Baveno Ⅴ consensus workshop on methodology of diagnosis and therapy in portal hypertension[J]. J Hepatol,2010,53(4):762-768. [7] de Franchis R. Expanding consensus in portal hypertension: report of the Baveno Ⅵ Consensus Workshop: stratifying risk and individualizing care for portal hypertension[J]. J Hepatol,2015,63(3):743-752. [8] de Franchis R,Bosch J,Garcia-Tsao G,et al. Baveno Ⅶ-Renewing consensus in portal hypertension[J]. J Hepatol,2022,76(4):959-974. [9] Wang Q, Zhao H, Deng Y, et al. Validation of Baveno Ⅶ criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis[J]. J Hepatol, 2022, 77(6): 1564-1572. [10] Hui V W, Wong G L, Wong V W, et al. Baveno Ⅶ criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis[J]. JHEP Rep, 2023, 5(9): 100814. [11] Zhang Y, Liu X, Li S, et al. Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: a retrospective study based on Baveno VII criteria[J]. Hepatol Commun, 2024, 8(1):e0355. [12] World Health Organization. Global hepatitis report 2024: action for access in low-and middle-income countries[R]. Geneva:World Health Organization,2024. [13] He C,Liu P,Liu X,et al. Changing etiological spectrum of cirrhosis in China: a systematic review and meta-analysis[J/OL]. BMC Gastroenterol,2026.https://pubmed.ncbi.nlm.nih.gov/42286454/ [14] 戴二黑,郭心如,王继涛,等.肝硬化的病因及防治现状调查[J].中华医学杂志,2023,103(12):913-919. [15] You H,Wang F,Li T,et al. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)[J]. J Clin Transl Hepatol,2023,11(6):1425-1442. [16] Duo H,You J,Du S,et al. Liver cirrhosis in 2021: global burden of disease study[J]. PLoS One,2025,20(7):e0328493. |